Completed PHASE1 INTERVENTIONAL 1-arm NCT04238728

Silverlon to Reduce Radiation Dermatitis

An Unblinded, Open-label Study Evaluating the Safety of Silverlon to Manage Radiation Dermatitis.

Sponsor: Biomedical Advanced Research and Development Authority

Interventions Silverlon

Updated 11 times since 2020 Last updated: Mar 21, 2023 Started: Aug 31, 2020 Primary completion: Mar 1, 2022 Completion: Mar 25, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Radiation Dermatitis, this trial is completed. The trial is conducted by Biomedical Advanced Research and Development Authority and has accumulated 11 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

11 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Feb 2024 — Jul 2024 [monthly]

Completed PHASE1

Phase: PHASE1_PHASE2 → PHASE1
Apr 2022 — Feb 2024 [monthly]

Completed PHASE1_PHASE2

Status: Recruiting → Completed
Jan 2022 — Apr 2022 [monthly]

Recruiting PHASE1_PHASE2

▶ Show 6 earlier versions

Sep 2021 — Jan 2022 [monthly]

Recruiting PHASE1_PHASE2
Mar 2021 — Sep 2021 [monthly]

Recruiting PHASE1_PHASE2
Jan 2021 — Mar 2021 [monthly]

Recruiting PHASE1_PHASE2

Phase: NA → PHASE1_PHASE2
Oct 2020 — Jan 2021 [monthly]

Recruiting NA

Status: Not Yet Recruiting → Recruiting
Jun 2020 — Oct 2020 [monthly]

Not Yet Recruiting NA
Feb 2020 — Jun 2020 [monthly]

Not Yet Recruiting NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Biomedical Advanced Research and Development Authority
University of Rochester

Data source: University of Rochester

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rochester, United States